Giant-Cell Arteritis

Apr 23, 2024

Ipsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation

Mar 11, 2024

Giant-Cell Arteritis Treatment Beyond Glucocorticoids: Exploring Horizons

Newsletter/Whitepaper